An AstraZeneca representative stated in an email that the AZD1222 vaccine candidate contains the genetic material of the SARS-CoV-2 virus spike protein, and the changes in the genetic code of the new viral strain do not affect the structure of the spike protein. Drug manufacturers are rushing to test their COVID-19 vaccines against the highly contagious new variant of the virus spreading rapidly in Britain, presenting a new challenge in the race to control the pandemic. The representative also mentioned that through vaccination with AZD1222, the immune system is trained to recognize various parts of the spike protein to help eliminate the virus if exposed later on. The B.1.1.7 lineage mutation, which is more infectious and concerning for children, has caused turmoil in Britain, leading to travel bans that are disrupting trade with Europe and potentially isolating the country further. The AstraZeneca-Oxford vaccine is seen as important for poorer countries and regions with warm climates due to its affordability, ease of transport, and ability to be stored for extended periods at regular refrigerator temperatures. Recent data from AstraZeneca's trials in the UK and Brazil revealed that the vaccine had an efficacy of 62% for participants who received two full doses, but 90% for a smaller group who received a half dose followed by a full dose. Reuters reported on Tuesday that India is expected to authorize the emergency use of AstraZeneca's vaccine by the following week.